Literature DB >> 11684561

Comparing methods for monitoring serum creatinine to predict late renal allograft failure.

B L Kasiske1, M A Andany, D Hernández, J Silkensen, H Rabb, J McClean, J P Roel, B Danielson.   

Abstract

Few studies have systematically investigated what changes in chronic renal allograft function best predict subsequent graft failure, when these changes occur, and whether they occur soon enough to allow possible intervention. We collected serum creatinine values (mean, 183 +/- 75 values/patient) measured over a maximum follow-up of 22 years in 101 consecutive renal transplant recipients (excluding creatinine levels from periods of acute rejection). We determined the dates of first decline in inverse creatinine (Delta1/Cr; < -20%, -30%, -40%, -50%, and -70%), declines in estimated creatinine clearance (CCr; <55, 45, 35, 25, and 15 mL/min), and declines in measured slope of 1/Cr over time. We used time-dependent covariates in Cox proportional hazards analyses to determine the relative effect of each renal function parameter on outcomes while adjusting for other risk factors. The best predictor of subsequent graft failure was Delta1/Cr. Delta1/Cr less than -40% first occurred at a median of 1.28 years after transplantation in 73 patients, and 67 patients went on to have graft failure a median of 3.28 years after Delta1/Cr less than -40%. The independent relative risk for graft failure attributable to Delta1/Cr less than -40% was 5.91 (95% confidence interval, 3.25 to 10.8; P < 0.0001). A decline in CCr, eg, less than 45 mL/min, also was a strong predictor of subsequent graft failure. Conversely, declines in allograft function estimated from slopes of 1/Cr were poor predictors of graft failure. In analysis limited to patients followed up for 2.5 years or less, Delta1/Cr continued to predict graft failure, suggesting that Delta1/Cr will be a useful predictor in populations with shorter follow-up. If confirmed in other populations, eg, patients treated with calcineurin inhibitors, this simple marker of chronic allograft dysfunction may prove to be a practical tool for defining patients at high risk for late graft failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684561     DOI: 10.1053/ajkd.2001.28605

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.

Authors:  Pierre Merville
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Joint Modeling of Covariates and Censoring Process Assuming Non-Constant Dropout Hazard.

Authors:  Miran A Jaffa; Ayad A Jaffa
Journal:  Stat Methods Appt       Date:  2015-04-01

Review 3.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Evaluation of gene panel mRNAs in urine samples of kidney transplant recipients as a non-invasive tool of graft function.

Authors:  Valeria R Mas; Luciana A Mas; Kellie J Archer; Kenneth Yanek; Anne L King; Eric M Gibney; Adrian Cotterell; Robert A Fisher; Marc Posner; Daniel G Maluf
Journal:  Mol Med       Date:  2007 May-Jun       Impact factor: 6.354

5.  Variability of the Estimated Glomerular Filtration Rate in the First Year after Kidney Transplantation Is an Independent Risk Factor for Poor Renal Allograft Outcomes: A Retrospective Cohort Study.

Authors:  Hoon Young Choi; Kyu Ha Huh; Jae Geun Lee; Mi Kyung Song; Myoung Soo Kim; Yu Seun Kim; Beom Seok Kim
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

6.  An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies.

Authors:  Aurélie Prémaud; Matthieu Filloux; Philippe Gatault; Antoine Thierry; Matthias Büchler; Eliza Munteanu; Pierre Marquet; Marie Essig; Annick Rousseau
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.